Ocular Therapeutix Inc

OCUL

Add to Watchlist

9.160USD

-0.340-3.58%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

Ocular Therapeutix Inc's Score

Industry at a Glance

Industry Ranking

53 / 155

Overall Ranking

148 / 4482

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Ocular Therapeutix Inc Highlights

StrengthsRisks

Ocular Therapeutix, Inc. is a fully-integrated biopharmaceutical company. AXPAXLI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases and conditions of the eye.

Growing

The company is in a growing phase, with the latest annual income totaling USD 51.95M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 51.95M.

Fairly Valued

The company’s latest PE is -6.37, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 212.47M shares, increasing 5.74% quarter-over-quarter.

Held by Paul Tudor Jones

Star Investor Paul Tudor Jones holds 494.79K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.12.

Analyst Rating

Based on 12 analysts

Buy

Current Rating

25.636

Target Price

+169.86%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Ocular Therapeutix Inc is 6.39, ranking 139 out of 155 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 10.79M, representing a year-over-year increase of 0.81%, while its net profit experienced a year-over-year increase of 38.34%.

Score

Industry at a Glance

Previous score

6.39

Change

0



Financials

9.30

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.57

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.72

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.26

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Ocular Therapeutix Inc is 6.61, ranking 116 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is -6.37, which is -62.52% below the recent high of -2.39 and -76.28% above the recent low of -11.23.

Score

Industry at a Glance

Previous score

6.61

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 53/155

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Ocular Therapeutix Inc is 8.67, ranking 12 out of 155 in the Pharmaceuticals industry. The average price target is 22.50, with a high of 31.00 and a low of 18.00.

Score

Industry at a Glance

Previous score

8.67

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Ocular Therapeutix Inc is 6.89, ranking 70 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 9.78 and the support level at 8.74, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.43

Change

-0.54

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Ocular Therapeutix Inc is 10.00, ranking 1 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 97.04%, representing a quarter-over-quarter increase of 9.08%. The largest institutional shareholder is PRFDX, holding a total of 2.90M shares, representing 1.33% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

30.97M

+66.78%

BlackRock Institutional Trust Company, N.A.

9.23M

-1.20%

Summer Road, LLC

12.13M

-3.54%

Avoro Capital Advisors LLC

10.25M

+38.51%

Deep Track Capital LP

11.93M

-16.53%

VR Adviser, LLC

13.16M

+3.13%

TCG Crossover Management, LLC

6.12M

+15.00%

Adage Capital Management, L.P.

4.00M

+2.93%

Geode Capital Management, L.L.C.

3.34M

+1.65%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Ocular Therapeutix Inc is 5.26, ranking 71 out of 155 in the Pharmaceuticals industry. The company's beta value is 0.92. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Ocular Therapeutix Inc

OCUL

7.23 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Catalyst Pharmaceuticals Inc

CPRX

9.11 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Jazz Pharmaceuticals PLC

JAZZ

8.81 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Royalty Pharma PLC

RPRX

8.72 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Kiniksa Pharmaceuticals International PLC

KNSA

8.59 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

8.52 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment